MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.280
+0.030
+2.40%
After Hours: 1.280 0 0.00% 16:51 07/28 EDT
OPEN
1.280
PREV CLOSE
1.250
HIGH
1.340
LOW
1.230
VOLUME
1.94M
TURNOVER
--
52 WEEK HIGH
3.790
52 WEEK LOW
0.9895
MARKET CAP
126.74M
P/E (TTM)
-2.2841
1D
5D
1M
3M
1Y
5Y
BRIEF-Abeona Therapeutics Reports Second Quarter Financial Results
reuters.com · 1h ago
Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy
Abeona Therapeutics Inc (NASDAQ: ABEO) 
Benzinga · 6h ago
Abeona completes Type B meeting with FDA for ABO-102 in Sanfilippo syndrome type A
Abeona Therapeutics (ABEO) perks up 4% premarket in reaction to the company's announcement that it has successfully completed Type B meeting with the FDA for its AAV-based gene therapy ABO-102 for the
Seekingalpha · 9h ago
BRIEF-Abeona Therapeutics Announces Successful Type B Meeting With U.S. FDA
reuters.com · 9h ago
Abeona Therapeutics Reports Completed Type B Meeting With FDA For ABO-102 Gene Therapy In Sanfilippo Syndrome Type A
Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease Alignment with FDA on primary study endpoint NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc.
Benzinga · 9h ago
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease
GlobeNewswire · 9h ago
34 Stocks Moving in Tuesday's Pre-Market Session
Gainers Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares rose 139.7% to $7.48 in pre-market trading after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics for roughly $7.1 million.
Benzinga · 1d ago
48 Stocks Moving In Monday's Mid-Day Session
Gainers Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The stock is also trading higher in sympathy with the price of Bitcoin.
Benzinga · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABEO. Analyze the recent business situations of Abeona through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABEO stock price target is 4.667 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 40.77M
% Owned: 41.17%
Shares Outstanding: 99.02M
TypeInstitutionsShares
Increased
22
4.37M
New
17
635.29K
Decreased
20
4.18M
Sold Out
13
2.06M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.64%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Chairman/Executive Director
Steven Rouhandeh
President/Chief Executive Officer/Chief Operating Officer/Director
Michael Amoroso
Senior Vice President
Vishwas Seshadri
Chief Accounting Officer
Edward Carr
Director
Christine Silverstein
Independent Director
Leila Alland
Independent Director
Mark Alvino
Independent Director
Faith Charles
Independent Director
Paul Mann
Independent Director
Todd Wider
Independent Director
Donald Wuchterl
No Data
  • All
  • Financials
  • Insiders
More
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.